PepGen Inc. Common Stock
PEPGPepGen Inc. (PEPG) is a biotechnology company focused on the development of innovative gene delivery therapies for neurological and rare diseases. Utilizing proprietary proprietary peptide engineering and delivery platform technologies, PepGen aims to enhance the delivery and efficacy of oligonucleotide therapies to target tissues, including the central nervous system. The company's approach seeks to address limitations of existing treatments and expand therapeutic options for underserved patient populations.
Company News
The global Peptide Drug Conjugate (PDC) market is projected to reach $1.5 billion by 2031, growing at over 14% CAGR from 2021-2025. PDCs offer targeted drug delivery solutions for oncology and other diseases with reduced systemic toxicity. The market features over 50 clinical candidates and 18 proprietary technologies, with major players includin...
U.S. stocks traded lower midday, with the S&P 500 dropping 1%. Accenture reported strong Q4 earnings, beating analyst estimates, while several other companies experienced significant stock price movements.
PepGen Inc. experienced a significant 112.4% pre-market stock surge after announcing an underwritten public offering of common stock and pre-funded warrants. Several other stocks showed notable pre-market movements, with some gaining and others declining.
A class action lawsuit has been filed against PepGen alleging false and misleading statements about the company's drug PGN-EDO51, its CONNECT2 study effectiveness, and clinical prospects during the period of March 7, 2024 to March 3, 2025.
Law firm announces class action lawsuit against PepGen Inc. for allegedly making false and misleading statements about its drug PGN-EDO51 and clinical study CONNECT2 between March 2024 and March 2025.
